The China oncology drugs market size was valued at $15.79 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 13.1% from 2022 to 2030 and will reach $42.28 Bn in 2030. The China oncology drug market is segmented by disease, drug type, and end user. The factors driving the oncology drugs market in China are the increasing interest of people in partnerships and trends of research in drugs. A few key players in the oncology drugs market in China are Bio-Thera, I-Mab, Beigene, and Alphamab.
The China oncology drugs market size was valued at $15.79 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 13.1% from 2022 to 2030 and will reach $42.28 Bn in 2030. The largest sector of the pharmaceutical industry is oncology medications. Its growth rate is anticipated to stay extremely high. Immuno-oncology is mainly responsible for this growth. Due to the market's dominance by a relatively small number of expensive drugs, individual therapies are frequently very expensive. Wealthier nations produce the majority of the revenue. Oncology is a major market for several top pharmaceutical companies.
The market size is somewhat smaller than anticipated as a result of the COVID-19 pandemic. This is brought on by the harder access to medications prescribed by doctors. Additionally, fewer new cases were found as a result of fewer medical exams and screenings. China is anticipated to dominate the APAC market as a result of increased government spending on enhancing healthcare infrastructure in the area and efforts to increase domestic production of high-quality pharmaceuticals.
Market Growth Drivers Analysis
The number of Chinese businesses funding research and potentially partnering with multinational corporations to penetrate developed markets has been steadily increasing. Due to increased access to new treatments and price reductions, China's oncology spending has surpassed that of the other developing nations in the pharmaceutical industry.
Market Restraints
Mainland China keeps falling short of the US, EU, and Japan in terms of the approval of new oncology medications. The US, the EU, and Japan approve new oncology drugs 94% more quickly than China does.
Key Players
61 oncology novel active substances (NASs) were introduced in China over the course of the most recent five years, compared to just 41 from 2002 to 2016. This is most likely a result of regulatory expediting procedures from the National Medical Products Administration (NMPA) to speed up the distribution of medications developed both domestically and abroad to Chinese citizens. Every year, the Chinese government receives a large number of new medications for consideration for the National Reimbursement Drug List.
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
By Drug class
By Therapy
By Indication
By Dosage form
By Distribution channel
Methodology for Database Creation
Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.
Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.
How Do We Get It?
Our database is created and maintained through a combination of secondary and primary research methodologies.
1. Secondary Research
With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:
With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:
2. Primary Research
To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:
Combining Secondary and Primary Research
By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:
Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.